Genprex, Inc. (GNPX)
Nasdaq · Healthcare · Biotechnology
$2.72+3.42%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.2M
- 52-week range
- $2.53 – $1,210.00
- 52-week change
- −98.82%
- EPS (trailing)
- −$9.35
Fiscal year to Dec 2025
- Net income
- −$16.2M
From the company’s annual report on SEC EDGAR.
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. It also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistant NSCLC, other tumor suppressor genes, and Glioblastoma, which is in preclinical studies. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
Headquarters: Austin, United States · 13 employees · genprex.com